Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Geriatric drug trials on solid tumor are scarce worldwide.
Huang H, Cui D, Leng Y, Zhang K, Yu A, Wang Y, Wu H, Tang Y, Yu F, Li N. Huang H, et al. Among authors: yu a, yu f. Front Med (Lausanne). 2023 Feb 6;10:1063648. doi: 10.3389/fmed.2023.1063648. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36814778 Free PMC article.
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S, Chen R, Tang Y, Yu Y, Fang Y, Huang H, Wu D, Fang H, Bai Y, Sun C, Yu A, Fan Q, Gu D, Yi X, Li N. Wang S, et al. Among authors: yu a, yu y. Front Oncol. 2020 Apr 21;10:536. doi: 10.3389/fonc.2020.00536. eCollection 2020. Front Oncol. 2020. PMID: 32373528 Free PMC article.
[Acceptance and Related Causes of Clinical Trials among Cancer Patients in China].
Huang H, Fan Q, Fang H, Wu D, Wang S, Bai Y, Yu A, Wang H, Sun C, Yu Y, Fang Y, Yang S, Shi J, He R, Li N. Huang H, et al. Among authors: yu a, yu y. Zhongguo Fei Ai Za Zhi. 2020 Jan 20;23(1):41-49. doi: 10.3779/j.issn.1009-3419.2020.01.07. Zhongguo Fei Ai Za Zhi. 2020. PMID: 31948537 Free PMC article. Chinese.
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges.
Huang H, Tang Y, Yu Y, Yu A, Wu D, Fang H, Wang S, Sun C, Wang X, Fan Q, Fang Y, Tang Q, Jiang N, Du J, Miao H, Bai Y, Ma P, Xing S, Cui D, Miao S, Jiang Y, Zhu J, Zhu Q, Leng Y, Guo LW, Liao S, Shao Y, Song Y, Liu Z, Hong M, Luo S, Xu B, Lan G, Li N. Huang H, et al. Among authors: yu a, yu y. Lancet Reg Health West Pac. 2022 Nov 18;31:100624. doi: 10.1016/j.lanwpc.2022.100624. eCollection 2023 Feb. Lancet Reg Health West Pac. 2022. PMID: 36426285 Free PMC article. Review.
Targeting rare tumors: new focus for clinical research in China.
Wang S, Jiang Y, Miao H, Fang Y, Jiang N, Yu Y, Ma P, Tang Q, Cui D, Fang H, Huang H, Fan Q, Sun C, Yu A, Miao S, Du J, Zhu J, Wang Y, Li N. Wang S, et al. Among authors: yu a, yu y. EMBO Mol Med. 2023 Jan 11;15(1):e16415. doi: 10.15252/emmm.202216415. Epub 2022 Nov 28. EMBO Mol Med. 2023. PMID: 36437781 Free PMC article.
[Awareness and Influencing Factors of Clinical Trial Among Cancer Patients in China].
Huang H, Fang Y, Fang H, Wu D, Bai Y, Wang S, Yu A, Wang H, Sun C, Fan Q, Yu Y, Yang C, Shi J, He R, Li N. Huang H, et al. Among authors: yu a, yu y. Zhongguo Fei Ai Za Zhi. 2020 Jan 20;23(1):5-14. doi: 10.3779/j.issn.1009-3419.2020.01.02. Zhongguo Fei Ai Za Zhi. 2020. PMID: 31948532 Free PMC article. Chinese.
Clinical development of immuno-oncology in China.
Wu DW, Huang HY, Tang Y, Zhao Y, Yang ZM, Wang J, Wang SH, Yu Y, Fang Y, Fang H, Bai Y, Sun C, Fan Q, Yu AQ, Wang HL, Du CX, Chen K, Huang MD, Zhang Y, Li N, Xu BH, Sun Y, He J. Wu DW, et al. Lancet Oncol. 2020 Aug;21(8):1013-1016. doi: 10.1016/S1470-2045(20)30329-6. Lancet Oncol. 2020. PMID: 32758460 No abstract available.
The Landscape of Cell and Gene Therapies for Solid Tumors.
Wang S, Sun F, Huang H, Chen K, Li QJ, Zhang L, Wang E, Wang C, Zhang H, Yuan AQ, Chen B, Deng T, Liu Y, Sun J, Liu D, Yu Y, Fang Y, Jiang N, Wu D, Fang H, Bai Y, Xing S, Ni Y, Fan Q, Yu A, Sun C, Tang Y, Li N, Xu B, He J. Wang S, et al. Among authors: yu a, yu y. Cancer Cell. 2021 Jan 11;39(1):7-8. doi: 10.1016/j.ccell.2020.12.005. Cancer Cell. 2021. PMID: 33434513 Free article. No abstract available.
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S, Huang HY, Wu D, Fang H, Ying J, Bai Y, Yu Y, Fang Y, Jiang N, Sun C, Yu A, Fan Q, Xing S, Ni Y, Zhang W, Wu C, Ji X, Wang H, Guo Y, Tang Q, Wang Y, Tang Y, Li N. Wang S, et al. Among authors: yu a, yu y. BMJ Open. 2021 Jun 3;11(6):e044543. doi: 10.1136/bmjopen-2020-044543. BMJ Open. 2021. PMID: 34083331 Free PMC article.
4,501 results